Clinical/Therapeutic Approaches for Cannabinoid Ligands in Central and Peripheral Nervous System Diseases: Mini Review

Clin Neuropharmacol. 2016 Mar-Apr;39(2):94-101. doi: 10.1097/WNF.0000000000000132.

Abstract

Objective: Cannabinoids, the components of Cannabis sativa Linnaeus, interact with CB1 and CB2 receptors, which are located both in the central nervous system and in the periphery and thus may exert a widespread biological activity in the body. The main medicinal properties of cannabinoids include analgesic, anti-inflammatory, antitumor, appetite stimulation, antiemesis, and muscle relaxation effects. This mini review aims to explore existing clinical trials that investigated the use of cannabinoids in diseases affecting the nervous system.

Methods: We reviewed recent studies of cannabinoid-based therapy for disorders affecting central and peripheral nervous system in human subjects.

Results: There is evidence that cannabinoid-based drugs may effectively control some symptoms associated with nervous system dysfunction, especially various types of pain and neurologic disorders, although studies are limited.

Conclusions: The efficacy of cannabinoid drugs in the treatment of nervous system diseases should be verified in future large-scale randomized clinical trials.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Cannabinoids / therapeutic use*
  • Humans
  • Ligands
  • Nervous System Diseases / drug therapy*
  • Peripheral Nervous System Diseases / drug therapy*

Substances

  • Cannabinoids
  • Ligands